Abstract
The therapeutic effects of Comelian were studied in 59 patients with vertigo (27 with central vertigo, 32 with peripheral vertigo). The oral dose of Comelian was 300 mg daily for 4 weeks. The results are as follows:
1) An adverse reaction, a sensation of light headedness, occurred in 1 patient with central vertigo.
2) An exellent or good response was achieved in 53.8% of 26 patients with central vertigo, 78.1% of 32 patients with peripheral vertigo, and 67.2% of the 58 patients overall.
3) A stratified analysis in central vertigo patients showed that better results were achieved with Comelian° in females, in patients with cerebrovascular insufficiency, in patients with a relatively short duration of illness, and in patients without tinnitus.
4) A stratified analysis in peripheral vertigo patients showed no signifficant difference in effecacy, although there was an exellent response in 3 patients with a history of asthma.
Comelian° was determined to be usefull in the treatment of both central and peripheral vertigo.
